3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
28
Carcinoma, Non-Small-Cell Lung
27
Colorectal Neoplasms
17
Esophageal Squamous Cell Carcinoma
14
Stomach Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
13
Esophageal Neoplasms
12
Cholangiocarcinoma
10
Lung Neoplasms
9
Head and Neck Neoplasms
9
Uterine Cervical Neoplasms
8
Small Cell Lung Carcinoma
8
Triple Negative Breast Neoplasms
7
Rectal Neoplasms
7
Nasopharyngeal Carcinoma
6
Melanoma
5
Colonic Neoplasms
5
Recurrence
4
Pancreatic Neoplasms
4
Locally Advanced Rectal Cancer
4
Hodgkin Disease
4
Neoplasms
3
NSCLC
3
Lymphoma, Extranodal NK-T-Cell
3
Glioblastoma
3
Carcinoma, Transitional Cell
3
Biliary Tract Neoplasms
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Interventions
Cisplatin
28
Pemetrexed
22
Gemcitabine
10
Nivolumab
9
Carboplatin
9
pembrolizumab
8
tremelimumab
5
durvalumab
5
atezolizumab
5
Radiotherapy
5
Doxorubicin
4
Chemotherapy, Adjuvant
4
Vinorelbine
3
Ipilimumab
3
Bortezomib
3
Bevacizumab
3
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
sodium thiosulfate
2
sargramostim
2
niraparib
2
nintedanib
2
liposomal doxorubicin
2
lenvatinib
2
defactinib
2
cemiplimab
2
cediranib
2
amatuximab
2
Trabectedin
2
Neoadjuvant Therapy
2
Mitomycin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Mesothelioma, Malignant
×
tislelizumab
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn